Another observation reflecting the intimate association between BRD4, CDK9 and AR in prostate cancer is that cells that have acquired resistance to BRD4 inhibition exhibit adaptive responses to AR and CDK9 [149]. This evidence concerns the gene CDK9 and prostate carcinoma.